Resumen de acción RLF Relief Therapeutics Holding SA, empresa biofarmacéutica, se centra en la identificación, el desarrollo y la comercialización de productos novedosos, protegidos por patentes, para el tratamiento de enfermedades raras metabólicas, dermatológicas y pulmonares en Suiza, Europa, Norteamérica e internacionalmente. Saber más
Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Relief Therapeutics Holding SA Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Relief Therapeutics Holding Precios históricos de las acciones Precio actual de la acción CHF 4.25 Máximo en las últimas 52 semanas CHF 7.60 Mínimo de 52 semanas CHF 1.06 Beta -14.5 Cambio en 1 mes 7.32% Variación en 3 meses -22.73% Cambio de 1 año 145.66% Variación en 3 años -88.38% Variación en 5 años 962.50% Variación desde la OPV -78.75%
Noticias y actualizaciones recientes
Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial Dec 16
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Nov 11 Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million. Nov 05
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Oct 25
We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth Oct 09
Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Oct 08 Ver más actualizaciones
Relief Therapeutics Holding SA Announces Final Readout of PKU GOLIKE Clinical Trial Dec 16
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Nov 11 Renexxion, LLC signed a letter of intent to acquire Relief Therapeutics Holding SA (SWX:RLF) in a reverse merger transaction valued at $260 million. Nov 05
Relief Therapeutics Reports New Study Results for RLF-OD032 and Files Provisional Patents Oct 25
We Think Relief Therapeutics Holding (VTX:RLF) Can Easily Afford To Drive Business Growth Oct 09
Relief Therapeutics Holding SA Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Oct 08
Relief Therapeutics Holding SA Reports Positive Results from RLF-OD032 Proof-of-Concept Clinical Study for Phenylketonuria Oct 04
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-Of-Concept Study; Topline Results Expected in October 2024 Sep 18
New minor risk - Shareholder dilution Sep 15
Relief Therapeutics Holding SA's (VTX:RLF) Share Price Boosted 52% But Its Business Prospects Need A Lift Too Sep 03
Relief Therapeutics Holding SA (VTX:RLF) Surges 52% Yet Its Low P/S Is No Reason For Excitement Sep 03
Relief Therapeutics Holding SA Announces PKU GOLIKE Study Results Presentation at SSIEM 2024 Sep 02
Relief Therapeutics Holding SA to Report First Half, 2024 Results on Aug 30, 2024 Jun 28 Relief Therapeutics Holding Announces Michelle Lock Will Not Stand for Re-Election as A Member of the Board of Directors
Relief Therapeutics Holding SA, Annual General Meeting, Jun 27, 2024 May 31 Relief Therapeutics Announces Executive Changes
New major risk - Share price stability May 07
Full year 2023 earnings released: CHF8.35 loss per share (vs CHF4.81 loss in FY 2022) May 02
New minor risk - Financial data availability Apr 02 Relief Therapeutics Holding SA announced that it expects to receive CHF 50 million in funding from Global Emerging Markets and another investor Feb 28
Less than half of directors are independent Nov 28
Relief Therapeutics Holding Sa Announces CEO Changes Nov 22
First half 2023 earnings released: CHF5.10 loss per share (vs CHF2.55 loss in 1H 2022) Sep 19
New major risk - Financial position Sep 17 Relief Therapeutics Holding AG announced that it expects to receive CHF 5 million in funding Jun 17
Relief Therapeutics Holding AG, Annual General Meeting, Jun 20, 2023 May 26
Health Check: How Prudently Does Relief Therapeutics Holding (VTX:RLF) Use Debt? May 05
Relief Therapeutics Announces Enrollment of First Three Patients in Proof-Of-Concept Clinical Trial of Rlf-Td011 for the Treatment of Epidermolysis Bullosa Feb 14
RELIEF THERAPEUTICS Holding SA Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom Jan 17
Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of Olpruva™ for Patients with Urea Cycle Disorders Dec 28
Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc. Dec 22
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements Dec 20 Relief Therapeutics Holding AG Appoints Jeremy Meinen as Chief Financial Officer
No independent directors Nov 16
Relief Therapeutics Holding AG Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) Nov 07
RELIEF THERAPEUTICS Holding SA Promotes Paolo Galfetti to Chief Operating Officer Oct 14
Relief Therapeutics Holding SA Announces U.S. Launch of PKU GOLIKE Oct 11
Does Relief Therapeutics Holding (VTX:RLF) Have A Healthy Balance Sheet? Oct 04
Relief Therapeutics Holding AG Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa At Ann & Robert H. Lurie Children's Hospital of Chicago Sep 22
Relief Therapeutics Holding AG has filed an IPO. Aug 24
Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announce Tentative Settlement of Pending Litigation Aug 23
Relief Therapeutics Holding SA Appoints David McCullough as Head of U.S. Market Access, Effective August 22, 2022 Aug 17
RELIEF THERAPEUTICS Holding SA and Acer Therapeutics Inc. Announce That the European Commission Has Granted Orphan Drug Designation for Acer-001 in Maple Syrup Urine Disease Aug 13
Relief Therapeutics Holding Ag Announces U.S. Food and Drug Administration Accepts for Review Acer’s Resubmitted New Drug Application Aug 06 Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine Jul 18
Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application for ACER-001 Jun 22
Relief Therapeutics Expands U.S. Commercial Team May 24
Acer Therapeutics Inc. and Relief Therapeutics Holding AG Announce Presentation of Acer-001 Data At the Genetic Metabolic Dieticians International Conference May 08
Relief Therapeutics Holding AG, Annual General Meeting, May 31, 2022 May 06
Price target decreased to CHF0.41 Apr 27
No independent directors Apr 27
Relief Therapeutics Holding AG Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing Apr 26
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry? Apr 23
Acer Therapeutics Inc. and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting Apr 12
Relief Therapeutics Holding SA Files Trademark Application for RLF-100 with the U.S. Patent and Trademark Office Feb 08
Relief Therapeutics Holding AG Approves Election of Michelle Lock as New Member of the Board of Directors Jan 31
NRx Pharmaceuticals Files Counterclaim Against its Former Collaboration Partner, Relief Therapeutics Jan 13
Relief Therapeutics Reports Successful Conclusion of Patent Examination Procedure for Patent Application Entitled, 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-Induced Pneumonitis Dec 28
Relief Therapeutics Holding SA Announces New Safety Update on Aviptadil Dec 16
Chief Commercial Officer Christiaan L. J. Stijnen has left the company Dec 01
Relief Therapeutics Holding (VTX:RLF) Has Debt But No Earnings; Should You Worry? Sep 25
Relief Therapeutics Holding AG (SWX:RLF) completed the acquisition of APR Applied Pharma Research s.a. Jun 30
Acer Therapeutics Plans NDA Submission for Acer-001 in Third Quarter 2021 Following Pre-NDA Meeting with FDA May 26
Relief Provides Update on Progress and Plans with Acer-001 for the Treatment of Urea Cycle Disorders May 21
Relief Therapeutics Holding AG (SWX:RLF) signed binding term sheet to acquire APR Applied Pharma Research s.a. for CHF. May 05
New 90-day low: CHF0.27 Mar 11
Relief Therapeutics Successfully Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure Among Critically Iii Patients with Covid-19 Feb 25
NeuroRx and Relief Therapeutics Holding AG Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19 Feb 10
Director has left the company Feb 10
RELIEF THERAPEUTICS Holding AG Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors Feb 10
Relief Therapeutics Holding AG Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients Feb 08
New 90-day high: CHF0.46 Feb 01
Relief Therapeutics Holding Ag and Acer Therapeutics Inc. Announces the Companies Have Signed an Option Agreement Jan 26
Relief Therapeutics Holding AG (SWX:RLF) signed a binding term sheet to acquire AdVita Lifescience GmbH for €45 million. Jan 21
We Wouldn't Rely On Relief Therapeutics Holding's (VTX:RLF) Statutory Earnings As A Guide Jan 13
NeuroRx, Inc. and Relief Therapeutics Holding AG Conclude Enrollment in Their Phase 2B/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure Dec 30
Relief Therapeutics Holding Ag Appoints Christiaan L.J.J. Stijnen as Chief Commercial Officer Dec 23
NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure Dec 09
NeuroRx, Inc. and Relief Therapeutics Holding AG Announces Initial Successful Results from Expanded Access Use of RLF-100(TM) (Aviptadil) in Patients with Critical COVID-19 and Severe Comorbidity Nov 26
NeuroRx and Relief Therapeutics Announce Enrollment of 150 Patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure Nov 14
NeuroRx, Inc. and Relief Therapeutics Holdings AG Announces Continuation of RLF-100™ Trial for Treatment of COVID-19 Respiratory Failure Nov 07
New 90-day low: CHF0.35 Nov 04 Rentabilidad de los accionistas RLF CH Biotechs Mercado CH 7D 1.0% 10.5% 2.0% 1Y 145.7% 108.3% 4.2%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: RLF superó a la industria Swiss Biotechs, que obtuvo un rendimiento del 108.3% el año pasado.
Rentabilidad vs. Mercado: RLF superó al mercado Swiss, que obtuvo un rendimiento del 4.2% el año pasado.
Volatilidad de los precios Is RLF's price volatile compared to industry and market? RLF volatility RLF Average Weekly Movement 23.6% Biotechs Industry Average Movement 14.1% Market Average Movement 3.4% 10% most volatile stocks in CH Market 7.8% 10% least volatile stocks in CH Market 1.6%
Precio estable de las acciones: El precio de las acciones de RLF ha sido volátil durante los últimos 3 meses en comparación con el mercado Swiss.
Volatilidad a lo largo del tiempo: La volatilidad semanal de RLF ha aumentado de 16% a 24% en el último año.
Acerca de la empresa Relief Therapeutics Holding SA, empresa biofarmacéutica, se centra en la identificación, desarrollo y comercialización de productos novedosos, protegidos por patentes, para el tratamiento de enfermedades raras metabólicas, dermatológicas y pulmonares en Suiza, Europa, Norteamérica e internacionalmente. La empresa ofrece SETOFILM/ONDISSOLVE para las náuseas y los vómitos inducidos por la radioterapia y la quimioterapia, así como para las náuseas y los vómitos postoperatorios; OLPRUVA, un fenilbutirato sódico para el tratamiento de los trastornos del ciclo de la urea y la enfermedad de la orina con olor a jarabe de arce; y PKU GOLIKE para el tratamiento dietético de la fenilcetonuria. También desarrolla TYR GOLIKE, que ha completado el ensayo clínico de fase III para tratar la tirosinemia; y RLF-100, una forma sintética del péptido intestinal vasoactivo (VIP), que está en ensayo clínico de fase II para el tratamiento del síndrome de dificultad respiratoria aguda (SDRA) asociado al SDRA relacionado con COVID-19 y en ensayo preclínico para tratar la sarcoidosis pulmonar, la neumonitis inducida por inhibidores de puntos de control y la beriliosis crónica.
Mostrar más Resumen de fundamentos de Relief Therapeutics Holding SA ¿Cómo se comparan los beneficios e ingresos de Relief Therapeutics Holding con su capitalización de mercado? Estadísticas fundamentales de RLF Capitalización bursátil CHF 53.30m Beneficios(TTM ) -CHF 46.24m Ingresos (TTM ) CHF 8.60m
6.2x Ratio precio-ventas (PS)
-1.2x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de RLF Ingresos CHF 8.60m Coste de los ingresos CHF 2.70m Beneficio bruto CHF 5.90m Otros gastos CHF 52.13m Beneficios -CHF 46.24m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -3.69 Margen bruto 68.56% Margen de beneficio neto -537.79% Ratio deuda/patrimonio 0.02%
¿Cómo se ha desempeñado RLF a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/08 23:19 Precio de las acciones al final del día 2025/01/08 00:00 Beneficios 2024/06/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Relief Therapeutics Holding SA está cubierta por 2 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Alexandre Müller Research Dynamics Bob Pooler ValuationLAB AG
Mostrar 0 más analistas 
